Qiagen NV (QGEN) revenue breakdown
By product, Diagnostic solutions is the largest at 38% of fiscal 2025 revenue, growing 8% a year over 7 years.
By region, United States is the largest at 48% of fiscal 2025 revenue, growing 7% a year over 9 years.
Revenue by product
Fiscal years, as Qiagen NV reports them in its 10-K filings; fiscal 2025 total $2.1B.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostic solutions | — | — | $461M | $466M | $461M | $639M | $661M | $698M | $749M | $803M | 38% |
| Sample technologies | — | — | $547M | $548M | $804M | $851M | $797M | $663M | $642M | $661M | 32% |
| PCR/Nucleic acid amplification | — | — | $237M | $225M | $364M | $434M | $391M | $300M | $300M | $309M | 15% |
| Genomics/NGS | — | — | $163M | $184M | $166M | $245M | $225M | $239M | $234M | $242M | 12% |
| Other | — | — | $94M | $104M | $77M | $83M | $68M | $66M | $53M | $75M | 4% |
| Consumables and Related | $1.2B | $1.2B | — | — | — | — | — | — | — | — | — |
| Instruments | $172M | $175M | — | — | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Qiagen NV reports them in its 10-K filings; fiscal 2025 total $2.1B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $556M | $580M | $633M | $664M | $729M | $910M | $910M | $935M | $942M | $998M | 48% |
| Europe, Middle East and Africa | $428M | $463M | $490M | $487M | $682M | $814M | $733M | $625M | $648M | $713M | 34% |
| Asia Pacific, Japan and Rest of World | $282M | $301M | $319M | $317M | $363M | $430M | $410M | $321M | $298M | $291M | 14% |
| Other Americas | $72M | $73M | $60M | $58M | $97M | $98M | $88M | $85M | $90M | $88M | 4% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for QGEN.
Open QGEN in InvestinglyQuestions
Where does Qiagen NV make its money?
In fiscal 2025, by product: Diagnostic solutions $803M, Sample technologies $661M, PCR/Nucleic acid amplification $309M, Genomics/NGS $242M, Other $75M.
From Qiagen NV's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.